Venetoclax in Previously Treated Waldenström Macroglobulinemia

PURPOSE: BCL2 is overexpressed and confers prosurvival signaling in malignant lymphoplasmacytic cells in Waldenström macroglobulinemia (WM). Venetoclax is a potent BCL2 antagonist and triggers in vitro apoptosis of WM cells. The activity of venetoclax in WM remains to be clarified. PATIENTS AND MET...

Full description

Bibliographic Details
Main Authors:	Advani, R.H (Author), Allan, J.N (Author), Branagan, A.R (Author), Castillo, J.J (Author), Davids, M.S (Author), Demos, M.G (Author), Flynn, C.A (Author), Furman, R.R (Author), Guerrera, M.L (Author), Hunter, Z.R (Author), Kofides, A. (Author), Leventoff, C. (Author), Liu, X. (Author), Meid, K. (Author), Munshi, M. (Author), Patterson, C.J (Author), Sarosiek, S. (Author), Siddiqi, T. (Author), Treon, S.P (Author), Tsakmaklis, N. (Author), White, T.P (Author), Xu, L. (Author), Yang, G. (Author)
Format:	Article
Language:	English
Published:	NLM (Medline) 2022
Subjects:	adult Adult aged Aged Aged, 80 and over antineoplastic agent Antineoplastic Agents BCL2 protein, human Biomarkers, Tumor Bridged Bicyclo Compounds, Heterocyclic chemokine receptor CXCR4 clinical trial CXCR4 protein, human disease exacerbation Disease Progression female Female fused heterocyclic rings genetics human Humans male Male middle aged Middle Aged mortality multicenter study mutation Mutation MYD88 protein, human myeloid differentiation factor 88 Myeloid Differentiation Factor 88 phase 2 clinical trial Progression-Free Survival Prospective Studies prospective study protein bcl 2 Proto-Oncogene Proteins c-bcl-2 Receptors, CXCR4 sulfonamide Sulfonamides time factor Time Factors tumor marker United States venetoclax very elderly Waldenstroem macroglobulinemia Waldenstrom Macroglobulinemia
Online Access:	View Fulltext in Publisher

Internet

View Fulltext in Publisher

Venetoclax in Previously Treated Waldenström Macroglobulinemia

Internet

Similar Items